IP Library Granted Patent US 8,293,223
Granted Patent B2
US 8,293,223 · App. 13/251,059 · Granted Oct 23, 2012

Treatment of organ injuries and burns using placental stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,293,223
App. No.
13/251,059
Granted
Oct 23, 2012
Kind
B2
Abstract

The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom.

Claims (12)

1. A method of treating an individual who has an injury to skin, comprising administering to the individual therapeutically effective amount of isolated human placental stem cells, wherein said placental stem cells are:

OCT-4 + , CD34 − , CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SH3 + , SH4 + , SSEA3 − , and SSEA4 − , wherein OCT-4 is octamer binding protein 4;

OCT-4 + , CD34 − , SSEA3 − and SSEA4 − ;

OCT-4 + and CD34 − , and additionally SH3 + or SH4 + ; or

CD34 − and one or more of CD29 + , CD45 − , CD90 + , SH2 + , SH3 + , SH4 + , or MHC Class II − .

2. The method of claim 1 , wherein said placental stem cells are OCT-4 + , CD34 − , CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SH3 + , SH4 + , SSEA3 − , and SSEA4 − .

3. The method of claim 1 , wherein said placental stem cells are OCT-4 + , CD34 − , SSEA3 − and SSEA4 − .

4. The method of claim 1 , wherein said placental stem cells are OCT-4 + and CD34 − , and additionally SH3 + or SH4 + .

5. The method of claim 4 , wherein said isolated placental stem cells have at least one of the following characteristics: CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SSEA3 − , or SSEA4 − .

6. The method of claim 4 , wherein said isolated placental stem cells have at least the following characteristics: CD10 + , CD29 + , CD44 + , CD45 − , CD54 + , CD90 + , SSEA3 − , and SSEA4 − .

7. The method of claim 1 , wherein said placental stem cells are CD34 − and one or more of CD29 + , CD45 − , CD90 + , SH2 + , SH3 + , SH4 + , or MHC Class II − .

8. The method of claim 1 , wherein said injury is a burn or wounding of the skin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2012
From: HARIRI, ROBERT J.
To: ANTHROGENESIS CORPORATION
Reel/Frame 027823/0879 →